EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.690
https://www.valueinhealthjournal.com/article/S1098-3015(23)03820-2/fulltext
Title :
EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03820-2&doi=10.1016/j.jval.2023.09.690
First page :
Section Title :
Open access? :
No
Section Order :
10175